Adenovirus/PSA (Ad5-PSA) Vaccination for Prostate Cancer: Pre-Clinical and Clinical Development

Author(s): Daniel Vaena, David Lubaroff.

Journal Name: Current Cancer Therapy Reviews

Volume 8 , Issue 4 , 2012

Become EABM
Become Reviewer


The use of PSA (prostate-specific antigen) for its diagnostic utility in prostate cancer is a subject of discussion; however, due to its specificity to the prostate tissue, PSA remains a potential immunotherapy target. We developed a PSA-recombinant viral vector, adenovirus5-PSA (Ad5-PSA) that generated vigorous PSA-specific immune and antitumor responses in a prostate cancer mouse model. Using Ad5-PSA vaccine we successfully completed a Phase I clinical study and are conducting a Phase II trial. In this review, we summarize the clinical development of this Ad5-PSA vaccine as an immunotherapeutic agent and its potential utility for the treatment of prostate cancer.

Keywords: Ad5-PSA vaccine, prostate cancer, immunotherapy

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Page: [271 - 273]
Pages: 3
DOI: 10.2174/1573394711208040271
Price: $65

Article Metrics

PDF: 6